ClearView Wealth Gains APRA Approval for Zurich Financial Services Australia Acquisition Scheme

APRA Regulatory Approval Marks Major Progress for Zurich-ClearView Deal

ClearView Wealth Limited has announced it has received APRA approval, fulfilling a key regulatory condition for Zurich Financial Services Australia Limited's proposed acquisition. This approval meets the APRA Approval Condition Precedent specified in Section 6.4(a)(viii) of the Scheme Booklet, representing a critical advancement in the transaction process. The approval, mandated under the Financial Sector (Shareholdings) Act 1998 (Cth), was granted by the Treasurer of the Commonwealth of Australia or their delegate, enabling the scheme to proceed.

The acquisition was initially announced on 24 February 2026 through a scheme implementation deed between ClearView and Zurich. Securing APRA approval is a vital regulatory milestone for financial sector acquisitions in Australia, confirming the deal has passed prudential regulatory scrutiny. Nonetheless, the scheme's implementation still depends on other conditions, including shareholder and final court approvals, before completion.

Scheme Meeting Set for 27 July 2026 with Full Director Support

ClearView shareholders will vote on the acquisition proposal at a hybrid scheme meeting on Monday, 27 July 2026, at 10:00am Sydney time. All ClearView directors unanimously recommend shareholders vote in favor of the scheme, provided no Superior Proposal arises and the Independent Expert continues to affirm that the scheme benefits shareholders. Directors holding or controlling ClearView shares have pledged to vote all shares under their control in favor of the scheme, subject to these conditions.

Shareholders intending to vote by proxy must lodge the Scheme Meeting Proxy Form by 10:00am Sydney time on Saturday, 25 July 2026. Proxy appointments can be submitted as outlined in Section 3 of the Scheme Booklet or online at www.investorvote.com.au, requiring shareholders’ SRN or HIN and the Control Number from their proxy form. The Scheme Booklet, distributed to shareholders on 26 June 2026, provides detailed information on the scheme, voting instructions, and director interests, which shareholders should review thoroughly before voting.

ClearView Wealth’s Role in the Australian Financial Services Sector

ClearView Wealth Limited operates as a financial services provider in Australia, listed on the ASX under ticker CVW and registered under ABN 83 106 248 248. The acquisition by Zurich Financial Services Australia Limited, an international financial services company, triggers the Financial Sector (Shareholdings) Act 1998 (Cth) requirement for APRA approval due to foreign ownership considerations. This reflects the regulatory importance of ownership changes within the Australian financial sector.

The acquisition is structured as a members' scheme of arrangement, a common Australian takeover mechanism allowing court-approved share transfers. ClearView maintains shareholder records through the standard investor vote registry, indicating an active shareholder base expected to participate in the 27 July vote. Additional information is available at clearview.com.au for investors and stakeholders.

Outstanding Conditions Precedent Prior to Scheme Execution

Although APRA approval has been obtained, the scheme's implementation remains contingent on other conditions detailed in Section 6.4 of the Scheme Booklet. The immediate next step is shareholder approval at the scheme meeting on 27 July 2026. The unanimous director recommendation and insider shareholding commitments indicate management anticipates favorable shareholder support, though the final outcome depends on the broader shareholder vote and any potential Superior Proposal.

After shareholder approval, final court approval at the Second Court Hearing is required. This judicial review ensures the scheme's fairness and reasonableness for shareholders. All conditions precedent must be satisfied or waived before the scheme can be implemented. The timeline for these steps will become clearer following the shareholder meeting, with APRA approval marking significant progress toward completion.

Comprehensive Scheme Booklet Provided for Shareholder Review

The Scheme Booklet, distributed on 26 June 2026 and registered with ASIC on 23 June 2026 as "Proposed acquisition of ClearView by Zurich – Scheme Booklet registered by ASIC," contains critical information for shareholders. It includes the Independent Expert's opinion on the scheme’s benefits, details of ClearView directors’ interests in the company and transaction, and full scheme terms. The booklet also outlines voting procedures and how to attend the hybrid meeting or appoint a proxy.

Shareholders are strongly advised to read the Scheme Booklet thoroughly before voting. It covers transaction specifics, financial data, tax implications, and risk factors. Queries about the scheme or voting can be directed to the company secretariat at [email protected]. Investor inquiries regarding the transaction can be addressed to Trevor Franz at Lancaster Grove Capital via [email protected]. The booklet ensures shareholders have all necessary information to make informed decisions.

Acquisition Timeline and Important Dates

Since the initial announcement on 24 February 2026, the acquisition process has reached key milestones. The Scheme Booklet was registered by ASIC and released on 23 June 2026, then dispatched to shareholders on 26 June 2026. The proxy submission deadline is 10:00am Sydney time on Saturday, 25 July 2026, followed by the scheme meeting on Monday, 27 July 2026. These dates are critical for shareholder participation.

APRA approval, confirmed before the 22 July 2026 company update, cleared an essential regulatory step enabling shareholder voting. This regulatory process typically takes months, underscoring the transaction’s progress. Post shareholder vote, the Second Court Hearing will provide final judicial approval. The approximately five-month timeline from announcement to shareholder vote aligns with typical Australian scheme of arrangement processes, balancing regulatory and shareholder approval efficiency.

Director Shareholdings and Voting Commitments

All ClearView directors holding or controlling shares have committed to voting their shares in favor of the scheme, contingent on no Superior Proposal and the Independent Expert’s continued positive assessment. The Scheme Booklet discloses each director’s shareholdings and related arrangements, providing transparency for shareholders when considering the directors’ unanimous recommendation. This disclosure aids shareholders in evaluating potential conflicts of interest.

The unanimous director endorsement encourages shareholder support, though shareholders are reminded to consider director interests independently. Directors’ commitment to vote their shares in favor signals confidence in the deal, while the conditional nature of their recommendation highlights reliance on the Independent Expert’s validation of shareholder value.

Independent Expert Review and Shareholder Safeguards

The scheme includes an Independent Expert’s assessment confirming whether the acquisition is in ClearView shareholders’ best interests. The directors’ recommendation depends on the expert maintaining a conclusion that the scheme is fair and reasonable, providing shareholders with an impartial professional evaluation. This is a standard safeguard in Australian schemes of arrangement, ensuring shareholders receive objective analysis beyond management views. The Scheme Booklet contains the full Independent Expert report.

Final court approval adds another layer of protection, with the court reviewing the scheme’s fairness and the voting process integrity. The multi-stage approval process involving APRA, shareholders, and the court reflects Australia’s regulatory framework for significant financial sector transactions. These measures protect shareholders, especially minorities, ensuring the acquisition terms are equitable and the process transparent.

Next Steps and Guidance for Shareholders

ClearView shareholders should carefully study the Scheme Booklet for detailed voting instructions, scheme terms, and financial analysis. Those unable to attend the hybrid meeting on 27 July 2026 should appoint a proxy by submitting the Scheme Meeting Proxy Form before 10:00am Sydney time on 25 July 2026. Online proxy appointments are available at www.investorvote.com.au using SRN, HIN, and Control Number.

For questions about the scheme or voting, shareholders can contact the company secretariat at [email protected]. Investor-specific inquiries about the transaction can be directed to Trevor Franz at Lancaster Grove Capital via [email protected]. The outcome of the scheme meeting will be announced to shareholders and the market post 27 July 2026, with further updates on court approval and implementation timelines to follow if shareholder approval is obtained.